Companies covered: Novo Nordisk A/S (NYSE:NVO), Eli Lilly and Company (NYSE:LLY), Amgen Inc. (NASDAQ:AMGN), Merck & Company, Inc. (NYSE:MRK), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), Moderna (NASDAQ:MRNA), BioNTech SE (ADR) (NASDAQ:BNTX), Bristol-Myers Squibb Company (NYSE:BMY), Novartis AG (NYSE:NVS), Cabaletta Bio Inc. (NASDAQ:CABA), Kyverna Therapeutics Inc. (NASDAQ:KYTX), Pfizer, Inc. (NYSE:PFE), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), AbbVie Inc. (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Altimmune Inc. (NASDAQ:ALT), Aerovate Therapeutics Inc. (NASDAQ:AVTE), Madrigal Pharmaceuticals (NASDAQ:MDGL), Akero Therapeutics Inc. (NASDAQ:AKRO), 89bio Inc. (NASDAQ:ETNB), Insmed, Inc. (NASDAQ:INSM), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Intellia Therapeutics Inc. (NASDAQ:NTLA), CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), Immunome Inc. (NASDAQ:IMNM), Disc Medicine Inc. (NASDAQ:IRON), Apogee Therapeutics Inc. (NASDAQ:APGE), ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), TScan Therapeutics Inc. (NASDAQ:TCRX), Nuvalent Inc. (NASDAQ:NUVL), Inozyme Pharma Inc. (NASDAQ:INZY), Beam Therapeutics Inc. (NASDAQ:BEAM), Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), Scholar Rock Holding Corp. (NASDAQ:SRRK), y-mAbs Therapeutics Inc. (NASDAQ:YMAB), Abivax SA (NASDAQ:ABVX), BioVie Inc. (NASDAQ:BIVI), Equillium Inc. (NASDAQ:EQ), Organovo Holdings, Inc. (NASDAQ:ONVO), PDS Biotechnology Corporation (NASDAQ:PDSB)
Companies covered: Achieve Life Sciences (NASDAQ:ACHV), BioLineRx Ltd. (NASDAQ:BLRX), Biora Therapeutics Inc. (NASDAQ:BIOR), Bluejay Diagnostics Inc. (NASDAQ:BJDX), BriaCell Therapeutics Corp. (NASDAQ:BCTX), Pfizer, Inc. (NYSE:PFE), AbbVie Inc. (NYSE:ABBV), Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX), Tenax Therapeutics, Inc. (NASDAQ:TENX), United Therapeutics Corporation (NASDAQ:UTHR), Merck & Company, Inc. (NYSE:MRK), GlaxoSmithKline PLC (NYSE:GSK), Moderna (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ), Kenvue Inc. (NYSE:KVUE), Omeros Corporation (NASDAQ:OMER), InflaRx NV (NASDAQ:IFRX), Agilon Health Inc. (NYSE:AGL), BioVie Inc. (NASDAQ:BIVI), Elutia Inc. (NASDAQ:ELUT), Inozyme Pharma Inc. (NASDAQ:INZY), PDS Biotechnology Corporation (NASDAQ:PDSB), SELLAS Life Sciences Group Inc. (NASDAQ:SLS), Theravance Biopharma, Inc. (NASDAQ:TBPH), Virpax Pharmaceuticals Inc. (NASDAQ:VRPX)
Companies covered: Canopy Growth Corp. (NYSE:CGC), Tilray (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON), Innovative Industrial Properties, Inc. (NYSE:IIPR), WM Technology Inc. (NASDAQ:MAPS), Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Glass House Brands Inc. (OTCMKTS:GLASF), TerrAscend Corp. (OTCMKTS:TSNDF), Constellation Brands Inc (NYSE:STZ), Green Thumb Industries (OTCMKTS:GTBIF), Verano Holdings Corp. (OTCMKTS:VRNOF), AYR Wellness Inc. (OTCMKTS:AYRWF), Curaleaf Holdings (OTCMKTS:CURLF), Trulieve Cannabis Corp. (OTCMKTS:TCNNF), Cresco Labs Inc. (OTCMKTS:CRLBF), Charlotte’s Web Holdings Inc. (OTCMKTS:CWBHF), British American Tobacco PLC (ADR) (NYSE:BTI), Zyus Life Sciences Corp. (OTCMKTS:ZLSCF), Ascend Wellness Holdings Inc. (OTCMKTS:AAWH), Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), Turning Point Brands (NYSE:TPB)
Companies covered: Medtronic, Inc. (NYSE:MDT), Stryker Corporation (NYSE:SYK), Intuitive Surgical, Inc. (NASDAQ:ISRG), GE HealthCare Technologies Inc. (NASDAQ:GEHC), Johnson & Johnson (NYSE:JNJ), Globus Medical, Inc. (NYSE:GMED), NuVasive, Inc. (NASDAQ:NUVA), Orthofix International N.V. (NASDAQ:OFIX), Abbott Laboratories (NYSE:ABT), Zimmer Biomet Holdings Inc. (NYSE:ZBH), Penumbra Inc. (NYSE:PEN), Treace Medical Concepts Inc. (NASDAQ:TMCI), Avita Medical Inc. (NASDAQ:RCEL), LENSAR Inc. (NASDAQ:LNSR), Humacyte Inc. (NASDAQ: HUMA), DexCom, Inc. (NASDAQ:DXCM), Boston Scientific Corporation (NYSE:BSX), RxSight Inc. (NASDAQ:RXST), Integra LifeSciences Holdings Corporation (NASDAQ:IART), P3 Healthcare Partners Inc. (NASDAQ:PIII), Apollo Medical Holdings, Inc. (NASDAQ:AMEH), Viemed Healthcare Inc. (NASDAQ:VMD), InfuSystems Holdings, Inc. (NYSEAMERICAN:INFU), iCAD, Inc. (NASDAQ:ICAD), Augmedix Inc. (NASDAQ:AUGX), Alphatec Holdings, Inc. (NASDAQ:ATEC), Harrow Health Inc. (NASDAQ:HROW), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Modivcare Inc. (NASDAQ:MODV), Smith & Nephew SNATS, Inc. (NYSE:SNN), IDEXX Laboratories, Inc. (NASDAQ:IDXX), Hologic, Inc. (NASDAQ:HOLX), Siemens AG (OTCMKTS:SIEGY), Zoetis Inc. (NYSE:ZTS), Illumina, Inc. (NASDAQ:ILMN), Clearpoint Neuro Inc. (NASDAQ:CLPT), Xtant Medical Holdings Inc. (NYSEAMERICAN:XTNT), Materialise NV (NASDAQ:MTLS)
Companies covered: IVERIC bio Inc. (NASDAQ:ISEE), Disc Medicine Inc. (NASDAQ:IRON), Nuvalent Inc. (NASDAQ:NUVL), Apellis Pharmaceuticals Inc. (NASDAQ:APLS), Amgen Inc. (NASDAQ:AMGN), Horizon Therapeutics PLC (NASDAQ:HZNP), Ipsen ADR (OTCMKTS:IPSEY), Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA), BioNTech SE (ADR) (NASDAQ:BNTX), Theseus Pharmaceuticals Inc. (NASDAQ:THRX), Mersana Therapeutics Inc. (NASDAQ:MRSN), Argenx SE (ADR) (NASDAQ:ARGX), Genmab A/S - ADR (NASDAQ:GMAB), Janux Therapeutics Inc. (NASDAQ:JANX)), Johnson & Johnson (NYSE:JNJ), AbbVie Inc. (NYSE:ABBV), Seagen Inc. (NASDAQ:SGEN), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), Chinook Therapeutics Inc. (NASDAQ:KDNY), Pfizer, Inc. (NYSE:PFE), Lisata Therapeutics Inc. (NASDAQ:LSTA), Omeros Corporation (NASDAQ:OMER), Cidara Therapeutics Inc. (NASDAQ:CDTX), Gilead Sciences, Inc. (NASDAQ:GILD), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), United Therapeutics Corporation (NASDAQ:UTHR), Astria Therapeutics Inc. (NASDAQ:ATXS), Biomea Fusion Inc. (NASDAQ:BMEA), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Merck & Company, Inc. (NYSE:MRK), Abivax (OTCMKTS:AAVXF), EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT), GeoVax Labs, Inc. (NASDAQ:GOVX), Organovo Holdings, Inc. (NASDAQ:ONVO), Telesis Bio Inc. (NASDAQ:TBIO), Codex DNA, Inc. (NASDAQ:DNAY), TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
